Self-titration of inhaled corticosteroid and β

In mild asthma, as-needed budesonide-formoterol is superior or noninferior to maintenance budesonide plus as-needed short-acting β Participants were randomised 1:1 to as-needed budesonide-formoterol (200/6 μg Turbuhaler, one actuation) or maintenance budesonide (200 μg Turbuhaler, one actuation twice a day) with as-needed terbutaline (250 μg, two actuations) for 52 weeks. 110 participants had electronic monitors attached to their study inhalers which captured the time and date of every actuation. Key outcome measures were patterns of ICS and β Participants randomised to as-needed budesonide-formoterol had more days with no ICS use compared with maintenance budesonide (median total days of no use 156 The timing of ICS dose when self-titrated to β

Informations de copyright

Copyright ©ERS 2020.

Déclaration de conflit d'intérêts

Conflict of interest: C. Baggott reports grants from the Health Research Council of New Zealand, during the conduct of the study; support for meeting attendance from AstraZeneca and Novartis, outside the submitted work. Conflict of interest: J. Hardy reports grants from the Health Research Council of New Zealand, during the conduct of the study; travel costs from AstraZeneca, outside the submitted work. Conflict of interest: J. Sparks reports grants from the Health Research Council of New Zealand, during the conduct of the study. Conflict of interest: M. Holliday reports grants from the Health Research Council of New Zealand, during the conduct of the study. Conflict of interest: D. Hall reports grants from the Health Research Council of New Zealand, during the conduct of the study. Conflict of interest: A. Vohlidkova reports grants from the Health Research Council of New Zealand, during the conduct of the study. Conflict of interest: R. Hancox reports grants from the Health Research Council of New Zealand, during the conduct of the study; support for meeting attendance from AstraZeneca and Boehringer Ingelheim, fees for lectures from Menarini, outside the submitted work. Conflict of interest: M. Weatherall reports grants from the Health Research Council of New Zealand, during the conduct of the study. Conflict of interest: J. Fingleton reports grants from the Health Research Council of New Zealand, during the conduct of the study; grants, personal fees for lectures and support for meeting attendance from AstraZeneca, grants and personal fees for lectures from GlaxoSmithKline, grants from Genentech, personal fees for lectures and support for meeting attendance from Boehringer Ingelheim, outside the submitted work. Conflict of interest: R. Beasley reports grants from the Health Research Council of New Zealand, during the conduct of the study; grants and personal fees from AstraZeneca and GlaxoSmithKline, grants from Genentech, personal fees from Avillion and Theravance, outside the submitted work.